The implementation of artificial intelligence in healthcare’s prior authorization process is a subject of intense debate, with the U.S. government piloting programs that aim to streamline approvals while critics raise alarms about potential increases in wrongful denials and impacts on patient care. This complex issue touches upon the balance between cost containment, administrative efficiency, and the fundamental right of patients to receive timely, medically necessary treatments.
The Thorny Landscape of Prior Authorization
For many Americans, the process of obtaining pre-approval from their health insurance provider for recommended medical care is a familiar and often frustrating ordeal. This system, known as prior authorization, is intended to act as a safeguard against unnecessary medical spending and the overuse of certain services or technologies by ensuring that less costly, equally effective alternatives are considered. However, the reality for many patients and physicians is one of significant delays, leading to the abandonment of crucial treatments and prolonged periods of uncertainty.
Physician groups consistently voice concerns about the impact of prior authorization on patient care. A substantial majority of doctors report that these delays cause patients to suffer, sometimes to the point of forgoing recommended therapies while awaiting insurance company verification of medical necessity and eligibility. The subsequent appeals process, often required after an initial denial, adds further layers of time and complexity, exacerbating the patient’s distress and potentially worsening their health outcomes. The American Medical Association (AMA) has been a vocal advocate for reform, pushing for insurers to provide detailed clinical reasoning for denials and demanding greater transparency regarding the algorithms used in AI-driven decision-making.
The Promise and Peril of AI in Prior Authorization
The advent of artificial intelligence, with its capacity to rapidly process vast datasets, has been presented as a potential solution to the inefficiencies plaguing the prior authorization system. Proponents suggest that AI could theoretically expedite the approval of clearly justifiable claims, thereby reducing the frustrating wait times experienced by patients. This could theoretically free up valuable clinician time, allowing them to focus more on patient care rather than administrative hurdles.
However, the integration of AI into prior authorization is not without its detractors and significant concerns. A 2025 survey by the AMA revealed that a significant percentage of physicians—61%—worry that AI will lead to an increase in the wrongful denial of necessary medical treatments. This apprehension stems from the potential for AI algorithms, if not properly designed and overseen, to prioritize cost savings over clinical judgment, leading to a system that makes it easier to deny care rather than facilitate it. Health policy analyst Camm Epstein succinctly captured this sentiment, stating, "AI should be used to make appropriate care easier to approve, not necessary care easier to deny."
Government Initiatives and Evolving Policies
In an effort to address these systemic issues, the U.S. government has been exploring various avenues, including the deployment of AI. The Trump administration, for instance, has been piloting a program in six states designed to leverage AI for reducing unnecessary medical spending. This initiative, known as the WISeR (Wasteful and Inappropriate Service Reduction) Model, aims to combat waste and fraud within original Medicare by employing machine learning alongside human clinical review to scrutinize services deemed vulnerable to overuse and abuse. These services include procedures like skin and tissue substitutes, electrical nerve stimulator implants, and knee arthroscopy for osteoarthritis. The WISeR project is slated to run through December 2031.
Historically, prior authorization has been a prevalent practice in Medicare Advantage, the private insurance alternative to traditional Medicare, but its application in original Medicare has been limited. This expansion into original Medicare through AI-driven mechanisms has raised red flags among patient advocacy groups and some lawmakers.
Adding to the complexity, the government and private insurers have made efforts to reform prior authorization processes. A rule introduced by the Biden administration in 2024 mandated that insurers make prior authorization decisions within 72 hours for urgent requests and seven calendar days for non-urgent requests, with these timelines becoming effective for most public sector health plans in early 2026. Concurrently, the Trump administration pledged to further streamline prior authorization, and private insurers committed to standardizing electronic requests by 2027 and reducing the volume of services subject to prior authorization by 2026, targeting common procedures like colonoscopies and cataract surgeries.
The Broader Impact on Patients
The burden of prior authorization on the public is widely acknowledged. In Medicare Advantage plans, which now cover approximately 55% of Medicare-eligible seniors, insurers issue millions of claim denials annually based on prior authorization requirements. Federal government reports have highlighted instances where these plans have denied requests for essential services like skilled nursing and rehabilitation, raising significant concerns about patient access to medically appropriate care. The appeals process, while available, is often described as convoluted and time-consuming, leaving patients in a precarious situation where they may run out of time or treatment options.
A recent survey by the Commonwealth Fund underscored the widespread impact of these denials. In 2025, approximately one in five working-age adults with private insurance reported that they or a family member had been denied coverage for physician-recommended medical care. Of those experiencing a prior authorization denial, 41% reported a delay in their care, and over a quarter stated that their health condition worsened as a result.
Concerns Over Profit Motives and AI Oversight
A significant point of contention regarding AI-driven prior authorization, particularly within the WISeR model, is the financial incentive structure for participating vendors. These vendors earn a share of "averted expenditures," a model that critics argue could incentivize the rejection of care requests. This raises long-standing concerns about the potential for profit to be derived from denying patients medically necessary care. In response to these concerns, several lawmakers have introduced resolutions and amendments aimed at blocking funding for the WISeR model, citing potential threats to patient access.
The Trump administration appears to be navigating a dual approach to prior authorization. While expanding AI’s role in original Medicare, CMS also aims to reduce and streamline its use by private insurers. CMS Administrator Mehmet Oz has publicly warned insurance executives that they must alleviate the prior authorization burden voluntarily, or the federal government will intervene with regulations.
In an effort to demonstrate progress and potentially preempt further regulatory action, health plans have released data indicating a reduction in prior authorization requests. Between June 2025 and April 2026, requests reportedly declined by 11%. However, it remains unclear whether the rate of denials has concurrently decreased.
Insurers have also provided assurances that AI or algorithms are not used in isolation to deny prior authorization requests involving medical necessity or clinical considerations. They have pledged greater transparency regarding the clinical reasoning behind these decisions. While these commitments may assuage some concerns about the lack of human oversight in AI-driven decisions, placating all detractors is proving to be a formidable challenge.
The Future of Prior Authorization
The debate over AI in prior authorization is far from settled. Some experts believe that AI, if developed and implemented ethically, could indeed streamline processes, reduce administrative waste, and ultimately allow clinicians more time with their patients. However, the current trajectory, according to some critics, points towards an "arms race to deny faster and appeal faster," with an over-automation of a system that many argue should be fundamentally reformed or even eliminated in its current form. The success of AI in fixing prior authorization, rather than exacerbating its flaws, will depend on robust oversight, a commitment to transparency, and a primary focus on patient well-being over cost-cutting measures. The coming years will be critical in determining whether this technological advancement serves as a true solution or merely amplifies existing problems within the healthcare system.
